TY - JOUR
T1 - Salivary gland pleomorphic adenoma in the Netherlands
T2 - A nationwide observational study of primary tumor incidence, malignant transformation, recurrence, and risk factors for recurrence
AU - Valstar, M.H.
AU - de Ridder, M.
AU - van den Broek, E.C.
AU - Stuiver, M.M.
AU - van Dijk, B.A.C.
AU - van Velthuysen, M.L..F.
AU - Balm, A.J.M.
AU - Smeele, L.E.
N1 - With supplementary files
PY - 2017/3
Y1 - 2017/3
N2 - Introduction: Whereas salivary gland pleomorphic adenoma (SGPA) is the most common type of salivary gland tumor, little is known about its epidemiology because national cancer registries do not register this disease. Objectives: To establish SGPA incidence trends, rates of secondary malignant transformation and recurrence and associated factors in the Netherlands. Materials and methods: Data on incidence, epidemiology, secondary malignant transformation and recurrence were retrieved from the Dutch pathology registry (PALGA) for the years 1992, 1997, 2002, 2007, and 2012. Multivariate analysis was performed to discover the risk factors for recurrence. Results: 3506 cases of SGPA were recorded implying an overall European standardized rate of 4.2–4.9 per 100,000 person-years. Our figures showed a female preponderance (1:1.43) with an annual 1% rise in female incidence (95% confidence interval [CI]: 0.2–1.8) and a bimodal age distribution in women (p < 0.0001). The overall 20-year recurrence rate was 6.7%, and median time to first recurrence was 7 years. Positive and uncertain resection margins and younger age at diagnosis were risk factors for recurrence, with odds ratios (ORs) of 4.62 (95%CI 2.84–7.51), 4.08 (95%CI 2.24–7.43), and 0.42 (95%CI 0.29–0.63) respectively. Tumor locations in the minor salivary glands had lower odds of recurrence than tumors in the parotid (OR 0.24; 95% CI: 0.07–0.77; p < 0.016). Malignant transformation occurred in 0.15% of SGPAs (3.2% of recurrences). Conclusion: This first nationwide study clearly showed sex differences in SGPA epidemiology, possibly suggesting some underlying hormonal mechanism. Long-term recurrence risks were low, and secondary malignant transformation risks were very low.
AB - Introduction: Whereas salivary gland pleomorphic adenoma (SGPA) is the most common type of salivary gland tumor, little is known about its epidemiology because national cancer registries do not register this disease. Objectives: To establish SGPA incidence trends, rates of secondary malignant transformation and recurrence and associated factors in the Netherlands. Materials and methods: Data on incidence, epidemiology, secondary malignant transformation and recurrence were retrieved from the Dutch pathology registry (PALGA) for the years 1992, 1997, 2002, 2007, and 2012. Multivariate analysis was performed to discover the risk factors for recurrence. Results: 3506 cases of SGPA were recorded implying an overall European standardized rate of 4.2–4.9 per 100,000 person-years. Our figures showed a female preponderance (1:1.43) with an annual 1% rise in female incidence (95% confidence interval [CI]: 0.2–1.8) and a bimodal age distribution in women (p < 0.0001). The overall 20-year recurrence rate was 6.7%, and median time to first recurrence was 7 years. Positive and uncertain resection margins and younger age at diagnosis were risk factors for recurrence, with odds ratios (ORs) of 4.62 (95%CI 2.84–7.51), 4.08 (95%CI 2.24–7.43), and 0.42 (95%CI 0.29–0.63) respectively. Tumor locations in the minor salivary glands had lower odds of recurrence than tumors in the parotid (OR 0.24; 95% CI: 0.07–0.77; p < 0.016). Malignant transformation occurred in 0.15% of SGPAs (3.2% of recurrences). Conclusion: This first nationwide study clearly showed sex differences in SGPA epidemiology, possibly suggesting some underlying hormonal mechanism. Long-term recurrence risks were low, and secondary malignant transformation risks were very low.
KW - Carcinoma ex pleomorphic adenoma
KW - Epidemiology
KW - Head and neck neoplasms
KW - Hormone
KW - Incidence
KW - Malignant transformation
KW - Pleomorphic adenoma
KW - Recurrence
KW - Risk factor
KW - Salivary glands
UR - http://www.scopus.com/inward/record.url?scp=85010006373&partnerID=8YFLogxK
UR - https://pure.uva.nl/ws/files/28993942/1_s2.0_S1368837517300118_mmc1.docx
UR - https://pure.uva.nl/ws/files/28993944/1_s2.0_S1368837517300118_mmc2.docx
UR - https://pure.uva.nl/ws/files/28993946/1_s2.0_S1368837517300118_mmc3.docx
UR - https://pure.uva.nl/ws/files/28993948/1_s2.0_S1368837517300118_mmc4.docx
U2 - https://doi.org/10.1016/j.oraloncology.2017.01.004
DO - https://doi.org/10.1016/j.oraloncology.2017.01.004
M3 - Article
C2 - 28249655
SN - 1368-8375
VL - 66
SP - 93
EP - 99
JO - Oral Oncology
JF - Oral Oncology
ER -